LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN NANOBIOTIX S.A. AND LIANBIO ONCOLOGY LIMITEDLicense, Development and Commercialization Agreement • April 8th, 2022 • Nanobiotix S.A. • Pharmaceutical preparations
This License, Development and Commercialization Agreement (this “Agreement”) is entered into and effective as of May 11, 2021 (the “Effective Date”), by and between Nanobiotix S.A., a French société anonyme having its registered office located at 60 Rue de Wattignies, 75012, Paris, France, registered under number 447 521 600 (RCS Paris) (“Nanobiotix”), and LianBio Oncology Limited, a Hong Kong company limited by shares, having its principal place of business located at Room 1902, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong ( “Lian”). Nanobiotix and Lian are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • April 8th, 2022 • Nanobiotix S.A. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of June 4, 2021 (“Amendment No. 1 Effective Date”) by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“UT System”) and Nanobiotix S.A., with a place of business located at 60 Rue de Wattignies, 75012 Paris, France Nanobiotix (“Nanobiotix”) (MD Anderson and Nanobiotix each a “Party” and collectively the “Parties”).
